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Background: The precise relationship between risk factor burden and prevalence of peripheral artery disease (PAD)
in different vascular territories (PAD, carotid artery stenosis [CAS], and abdominal aortic aneurysms [AAAs]) is unclear.
Methods: We investigated the association of modiﬁable risk factors (hypertension, hypercholesterolemia, smoking,
diabetes, and sedentary lifestyle) with any and type-speciﬁc peripheral vascular disease (PVD) among 3.3 million patients
in the U.S., aged 40 to 99, who underwent screening bilateral ankle brachial indices, carotid duplex ultrasound, and
abdominal aortic ultrasound in the Life Line Screening program between 2004 and 2008. Multivariate logistic regression
analysis was used to estimate the odds of disease in different risk factor categories. Population-attributable risk was
calculated to estimate the proportion of disease that could be potentially ascribed to modiﬁable risk factors.
Results: Among 3,319,993 participants, prevalence of any PVD was 7.51% (95% conﬁdence interval [CI], 7.50%-7.53%).
PAD was present in 3.56% (95% CI, 3.54%-3.58%), CAS in 3.94% (95% CI, 3.92%-3.96%), and AAAs in 0.88% (95% CI,
0.86%-0.89%). The multivariate-adjusted prevalence with the presence of 0, 1, 2, 3, 4, and 5 modiﬁable risk factors was
2.76, 4.63, 7.12, 10.73, 16.00, and 22.08 (P < .0001 for trend) for any PVD; 1.18, 2.09, 3.28, 5.14, 8.32, and 12.43
(P < .0001 for trend) for PAD; 1.41, 2.36, 3.72, 5.73, 8.48, and 11.58 (P < .0001 for trend) for CAS; and 0.31, 0.54,
0.85, 1.28, 1.82, and 2.39 (P < .0001 for trend) for AAAs, respectively. These associations were similar for men and
women. For every additional modiﬁable risk factor that was present, the multivariate-adjusted odds of having vascular
disease increased signiﬁcantly (any PVD [odds ratio (OR), 1.58; 95% CI, 1.58-1.59]; PAD [OR, 1.62; 95% CI, 1.62-
1.63]; CAS [OR, 1.57; 95% CI, 1.56-1.57]; and AAA [OR, 1.51; 95% CI, 1.50-1.53]).
Conclusions: This very large contemporary database demonstrates that risk factor burden is associated with an increased
prevalence of PVD, and there is a graded association between the number of risk factors present and the prevalence of
PAD, CAS, and AAAs. (J Vasc Surg 2013;58:673-81.)Atherosclerotic cardiovascular disease continues to
pose a major health burden.1,2 Recent studies have empha-
sized the importance of calculating risk for coronary artery
disease (CAD).1,3 However, many adults in the United
States who are considered to be at low risk for CAD may
still be at heightened risk for disease in other vascular terri-
tories.2 Prospective cohort studies as well as national
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://dx.doi.org/10.1016/j.jvs.2013.01.053vascular disease (PVD) have an increased risk of cardiovas-
cular and other morbidity and mortality with signiﬁcant
impairment of their quality of life.2,4 Estimates of the prev-
alence and risk of PVD may provide a more comprehensive
assessment of the overall burden of atherosclerotic disease.
Such estimates can potentially help guide public health
policy, target appropriate individuals for screening of
PVD, and allow projections of the overall burden of PVD
in the U.S. population. Additionally, knowledge of the
effects of modiﬁable risk factors and their relation to the
prevalence of PVD is critical on both an individual patient
and societal level in any attempt to reduce the frequency of
PVD and related complications.
Most previous epidemiologic estimates of the risk of
PVD have been performed in small populations, were
restricted to a single sex, or analyzed a single type of
vascular disease.5,6 In the current study, our objective
was to analyze a cohort of more than 3 million men and
women of different ages and different racial and ethnic
backgrounds to provide an opportunity to calculate esti-
mates of the prevalence and risk of PVD in different arterial
territories (peripheral artery disease [PAD] of the lower
extremities, carotid artery disease, and abdominal aortic
aneurysms [AAAs]) according to age, sex, race, and
other risk factors. Additionally, we calculated the popula-
tion-attributable risk (PAR) and 95% conﬁdence intervals
(CIs) to estimate the proportion of PVDs occurring in673
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674 Berger et al September 2013this population that hypothetically could be ascribed to
modiﬁable risk factors.METHODS
Study population. The study was based on data
provided by Life Line Screening Inc (LLS, Independence,
Ohio) for purposes of research. The data were provided
without any ﬁnancial considerations and without any
editorial control over analyses or resulting publications.
The study cohort consists primarily of self-referred individ-
uals who paid for the vascular screening tests out of pocket.
Screenings were performed during the years 2003 through
2008 at more than 20,000 screening sites nationwide rep-
resenting all 50 states and broad geographical and socio-
economic representation. A variety of costs were incurred
by the individuals based on the desired package of tests
purchased. Before undergoing screening examinations,
individuals completed an extensive questionnaire that in-
cluded information on demographics, smoking, exercise,
cardiovascular risk factors, medical comorbidities, and
family history of atherosclerosis and vascular disease.
Ascertainment of PVD. PAD, carotid artery disease,
and AAAs can be determined with simple noninvasive
procedures that have high sensitivity and speciﬁcity using
the ankle brachial index (ABI), carotid duplex ultrasound,
and abdominal aortic ultrasound, respectively.7 To calcu-
late the ABI, systolic blood pressure was measured in both
arms (brachial arteries) and both ankles (posterior tibial
arteries). If a posterior tibial Doppler signal was inaudible,
the dorsalis pedis artery signal was measured. Left and right
ABI measurements were obtained by dividing the systolic
occlusion pressure in the ankle by the highest arm pressure.
PAD was deﬁned as an ABI <0.90 in either leg. Carotid
artery disease was deﬁned by carotid artery stenosis (CAS)
$50% using duplex ultrasound criteria (internal carotid
artery peak systolic velocity $125 cm/s).8 The greater of
the anteroposterior or transverse ultrasound-based
measurements of the infrarenal abdominal aorta was used
to identify aortic size. AAA was deﬁned by a diameter of
the abdominal aorta $3 cm. For the current article, PVD is
deﬁned by any vascular disease in the lower extremities
(eg, PAD), carotid arteries (eg, CAS), or abdominal aorta
(eg, AAA).
Other variables of interest. We considered ﬁve modi-
ﬁable risk factors in our analyses. Hypertension was deﬁned
as systolic blood pressure of 140 mm Hg or greater in up-
per extremity, prior physician diagnosis, or medication use.
Hypercholesterolemia was deﬁned as physician diagnosis or
medication use. Diabetes was deﬁned as self-reported phy-
sician diagnosis or the use of diabetes medication. Subjects
who had smoked 100 cigarettes during their lifetime and
were still currently smoking were considered current
smokers. Subjects who had smoked 100 cigarettes during
their lifetime and were not currently smoking were con-
sidered former smokers. Subjects who reported engagement
in some kind of vigorous leisure time exercise on a regular
basis at least once per week were considered active and allother subjects were considered sedentary. Race and eth-
nicity were self reported.
The original data set included 4,153,627 screening
records obtained from 3,696,778 individuals. To distin-
guish an individual with multiple screenings, each individual
was assigned a unique identiﬁer. The investigators had ac-
cess only to deidentiﬁed “coded” data. The code was not
accessible to the investigators. When multiple screenings
were performed on the same individual, only the ﬁrst record
with complete information was included.
Statistical analysis. We calculated the proportion of
participants affected with vascular disease and examined
sex-speciﬁc, age-speciﬁc, and race/ethnicity-speciﬁc vas-
cular disease rates. The corresponding 95% CIs are re-
ported to present uncertainty associated with the estimated
prevalence.
We used logistic regression model to calculate the odds
ratio (OR) accompanied by 95% CIs to examine strength
of association between certain risk factors and prevalence
of PVD. To examine a modifying role of sex and race/
ethnicity, ORs and CIs are reported within stratum deﬁned
by sex and race/ethnicity. Further, ORs and CIs are esti-
mated based on a multivariate logistic regression model
that controls for age, sex, race/ethnicity, body mass index,
family history of cardiovascular disease, and each of the ﬁve
modiﬁable risk factors (hypertension, smoking, diabetes,
hypercholesterolemia and sedentary lifestyle).
We calculated the PAR and 95% CIs to estimate the
proportion of PVDs occurring in this population that
hypothetically could have been prevented (assuming a
causal relationship) if all participants had zero modiﬁable
risk factors present. For these analyses, we compared sub-
jects with a healthy lifestyle group (for each risk factor indi-
vidually and in combination) with the rest of the subjects in
the population. PAR estimates were derived using the
Levin formula9:
PAR ¼ prevalence  ðOR  1Þ
1þ ðprevalence  ðOR  1ÞÞ;
where prevalence is the prevalence of exposure to the risk
factor in the population. We estimated ORs and the corre-
sponding PAR based on a multivariate logistic regression
model while adjusting for age, sex, race/ethnicity, body
mass index, family history of cardiovascular disease, and
the modiﬁable lifestyle factors for each of the vascular
diseases. Then, the association between combinations of
modiﬁable risk factors with prevalence of vascular disease
was analyzed in women and men separately.
All statistical analyses were performed with PASW for
Windows (v. 18.0; SPSS Inc, Chicago, Ill), SAS software
for Windows (v. 9.12; SAS Institute Inc, Cary, NC), and
the R package (R Development Core Team).
RESULTS
Of the 3.6 million participants in the Lifeline screen-
ing program, 3,319,993 were included for the current
analysis; 107,318 were excluded because the ABI, carotid
Table I. Baseline characteristics of study participants
included in the analysis
Characteristic
Study participants
(n ¼ 3,696,778)
Age, years, 6 SD 64.1 6 10.2
Female sex, % 62.5
Race or ethnic group, %
White 85.8
Black 3.0
Hispanic 2.37
Asian 1.93
Native American 2.76
Other 0.62
Body mass index, kg/m2, 6 SD 27.4 6 6.07
Obesity,a % 27.6
Cigarette smoking status, %
Never smoked 59.65
Former smoker 30.78
Current smoker 23.48
Hypertension, % 47.0
Hyperlipidemia, % 53.3
Diabetes mellitus, % 10.8
Sedentary lifestyle, % 58.2
Family history of cardiovascular disease, % 23.0
SD, Standard deviation.
aObesity is deﬁned by a body mass index >30 kg/m2.
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recorded, and 269,467 were excluded because of any
missing data. There were small differences between the
remaining 3.3 million included in the analysis and the
374,785 excluded (Supplementary Table, online only).
General population characteristics. Among the par-
ticipants included in the analysis, the mean age was 64.1
years, and 62.5% were female (Table I). Twenty-three
percent were current smokers, 47% had hypertension, 53%
hyperlipidemia, and 11% had diabetes mellitus. Caucasians
comprised 85.8% of the subject population, but there were
meaningful numbers of blacks (n ¼ 111,456), Hispanics
(n ¼ 87,615), Asians (n ¼ 71,198), and Native Americans
(n ¼ 102,163).
Prevalence of PVD. The prevalence of any type of
PVD was 7.51% (95% CI, 7.50-7.53). PAD was present in
3.56% (3.54-3.58), carotid artery disease in 3.94% (3.92-
3.96), and AAAs in 0.88% (0.86-0.89). Fig 1 shows the
prevalence of any PVD, PAD, CAS, and AAA stratiﬁed by
sex, race/ethnicity, and age.
Males were more likely than females to have any
PVD (8.4% vs 7.0%). Males were more likely to have
CAS (4.6% vs 3.6%) and AAAs (1.9% vs 0.3%), but females
were more likely to have PAD (3.8% vs 3.1%). The preva-
lence of PVD differed signiﬁcantly by race and ethnicity
(Table II). Native American men had the highest preva-
lence of any PVD and Asian women had the lowest preva-
lence of any PVD. PAD was most common in black
women and least common in Asian men. CAS and AAAs
were most common in Native American men and least
common in Asian women. As expected, the prevalence of
any PVD, PAD, CAS, and AAA increased signiﬁcantly
with age (Fig 2).
Univariate analysis between modiﬁable risk factors
and vascular disease. The presence of traditional modiﬁ-
able atherosclerotic risk factors all were found to be signiﬁ-
cantly associated with the prevalence of any vascular disease
with the following ORs: diabetes, 2.19 (95% CI, 2.17-
2.22); hypertension, 2.18 (95% CI, 2.16-2.2); current
smoking, 1.87 (95% CI, 1.85-1.88); hyperlipidemia, 1.57
(95% CI, 1.56-1.58), former smoking, 1.54 (95% CI,
1.53-1.55); and sedentary lifestyle, 1.25 (95% CI, 1.24-
1.26) (Table III).
Similar ﬁndings were noted in the individual analysis of
PAD, with the most signiﬁcant association noted for dia-
betes (OR, 2.38; 95% CI, 2.34-2.41) and hypertension
(OR, 2.26; 95% CI, 2.23-2.36). In individual analysis of
CAS, the most signiﬁcant associations were also noted for
hypertension (OR, 2.26; 95% CI, 2.23-2.28) and diabetes
(OR, 2.18; 95% CI, 2.15-2.21). For AAAs, the most signif-
icant associations were noted for active smoking (OR,
3.14; 95% CI, 3.06-3.22) and former smoking (OR,
2.57; 95% CI, 2.51-2.63) (Table III).
Multivariate analysis between modiﬁable risk
factors and vascular disease. In multivariate analysis, the
presence of traditional atherosclerotic risk factors all were
found to be signiﬁcantly associated with the prevalence
of any vascular disease with the following ORs: currentsmoking, 2.06 (95% CI, 2.03-2.08); former smoking,
1.51 (95% CI, 1.49-1.53); diabetes, 1.60 (95% CI, 1.58-
1.62); hypertension, 1.59 (95% CI, 1.57-1.62); hyperlipid-
emia, 1.28 (95% CI, 1.26-1.31); and sedentary lifestyle,
1.31 (95% CI, 1.29-1.33) (Table III).
Similar ﬁndings were noted in the individual multivar-
iate analysis of PAD, with the most signiﬁcant associations
noted for active smoking (OR, 2.26; 95% CI, 2.23-2.29)
and diabetes (OR, 1.77; 95% CI, 1.74-1.79). In multivar-
iate analysis of CAS, the most signiﬁcant associations were
noted for active smoking (OR, 1.77; 95% CI, 1.75-1.8)
and hypertension (OR, 1.62; 95% CI, 1.59-1.64). For
AAAs, the most signiﬁcant associations in multivariate anal-
ysis were noted for active smoking (OR, 2.75; 95% CI,
2.68-2.82) and former smoking (OR, 1.98; 95% CI,
1.86-2.03).
PAR. In the overall study population, 21.7% (95%
CI, 21.4-22.0) and 20.1% (95% CI, 19.6-20.2) of any
vascular disease could hypothetically be attributed to
hypertension and active cigarette smoking, respectively
(Table IV). The other three modiﬁable risk factors were
also signiﬁcantly associated with vascular disease after
multivariate adjustment. Individual hypothetical PARs for
the other modiﬁable risk factors were much lower than
hypertension and active smoking; 13.0% (95% CI, 12.6-
13.4) for hyperlipidemia, 11.5% (95% CI, 11.1-11.8) for
sedentary lifestyle, and 6.1% (95% CI, 5.9-6.3) for diabetes.
Individual vascular phenotype PAR analysis was also
performed. For the individual vascular phenotype PARs,
23% of PAD could hypothetically be attributed to hy-
pertension and current smoking. For CAS, 23.4% could
hypothetically be attributed to hypertension and 20% to
Fig 1. Prevalence of any peripheral vascular disease (PVD), peripheral artery disease (PAD), carotid artery stenosis
(CAS), and abdominal aortic aneurysms (AAAs) (A) overall, (B) stratiﬁed by sex, (C) different race/ethnicity groups,
and (D) different age categories.
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current smoking and 19.7% to hyperlipidemia.
Association of aggregate risk factor burden. A
higher burden of modiﬁable risk factors was associated
with a higher prevalence of PVD (Fig 2; Table V).
Approximately 10% of the study population had an optimal
risk factor proﬁle (zero risk factors present), and in this
population, prevalence of PVD tended to be very low (<3%
for any vascular disease). The risk of vascular disease
became substantially higher with the presence of any single
risk factor. In general, nearly 1 in 20 individuals with
a single risk factor, 1 in 10 individuals with three risk
factors, or 1 in 5 individuals with all ﬁve risk factors had
PVD in at least one territory, respectively. A similar pattern
was noted for risk factor control and the individual preva-
lence of PAD, CAS, and AAAs (Table V).
The multivariate-adjusted ORs associated with risk
factor burden of 0 (reference group), 1, 2, and $3 mod-
iﬁable risk factors were 1, 1.51, 2.2, and 3.79 (P < .001
for trend) for any vascular disease; 1, 1.55, 2.29, and 3.98
(P < .001 for trend) for PAD; 1, 1.51, 2.25, and 3.88
(P < .001 for trend) for CAS; and 1, 1.53, 2.18, and
3.39 (P < .001 for trend) for AAAs (Table V). For every
additional modiﬁable risk factor that was present, theprevalence of vascular disease increased signiﬁcantly (any
PVD (OR, 1.58; 95% CI, 1.58-1.59); PAD (OR, 1.62;
95% CI, 1.62-1.63); CAS (OR, 1.57; 95% CI, 1.56-
1.57); and AAA (OR, 1.51; 95% CI, 1.50-1.53). The asso-
ciation between additional modiﬁable risk factors and
vascular disease was similar for women and men (any
vascular disease [OR, 1.62; 95% CI, 1.62-1.63 in women
and OR, 1.52; 95% CI, 1.52-1.53 in men]; PAD [OR,
1.64; 95% CI, 1.63-1.65 in women and OR, 1.62; 95%
CI, 1.60-1.63 in men]; CAS [OR, 1.62; 95% CI, 1.61-
1.63 in women and OR, 1.49; 95% CI, 1.48-1.50 in
men]; and AAAs [OR, 1.75; 95% CI, 1.71-1.78 in women
and OR, 1.40; 95% CI, 1.38-1.41 in men]).
DISCUSSION
In this very large cross-sectional study, we describe the
prevalence and estimated risk of PVD according to sex,
race/ethnicity, age, and modiﬁable risk factors. There
were several important ﬁndings. First, our data strongly
reinforce the inﬂuence of traditional atherosclerotic risk
factors on the prevalence of PVD. The absence of tradi-
tional risk factors was associated with a very low prevalence
of PVD, yet, even a relatively low burden of these risk
factors was associated with a clinically relevant increase in
Table II. Prevalence and 95% CI of PVD disease by sex and race
Prevalence of any PVD
(95% CI)
Prevalence of PAD
(95% CI)
Prevalence of CAS
(95% CI)
Prevalence of AAA
(95% CI)
All subjects 7.51 (7.50-7.53) 3.56 (3.54-3.58) 3.94 (3.92-3.96) 0.88 (0.86-0.89)
Men
Race/ethnicity
White 8.47 (8.41-8.52) 3.04 (3.00-3.07) 4.61 (4.57-4.65) 1.99 (1.97-2.02)
Black 8.20 (7.9-8.5) 5.43 (5.19-5.69) 2.57 (2.40-2.75) 1.02 (0.92-1.14)
Asian 4.61 (4.34-4.89) 1.79 (1.62-1.96) 2.50 (2.31-2.71) 0.80 (0.69-0.92)
Hispanic 4.74 (4.5-5.0) 1.95 (1.8-2.39) 2.56 (2.38-2.75) 0.75 (0.66-0.86)
Native American 13.81 (13.4-14.22) 5.67 (5.4-5.9) 7.56 (7.25-7.88) 2.9 (2.7-3.11)
Other 7.23 (6.66-7.85) 3.06 (2.69-3.48) 3.68 (3.27-4.14) 1.37 (1.13-1.67)
Women
Race/ethnicity
White 6.82 (6.78-6.85) 3.61 (3.59-3.64) 3.6 (3.58-3.63) 0.29 (0.29-0.30)
Black 8.91 (8.7-9.11) 6.79 (6.6-6.96) 2.56 (2.45-2.68) 0.28 (0.24-0.32)
Asian 4.1 (3.9-4.3) 2.37 (2.23-2.51) 1.86 (1.74-1.99) 0.09 (0.07-0.12)
Hispanic 4.25 (4.08-4.42) 2.39 (2.26-2.52) 2.04 (1.92-2.16) 0.10 (0.07-0.13)
Native American 11.42 (11.18-11.66) 6.35 (6.18-6.54) 5.90 (5.72-6.08) 0.56 (0.51-0.62)
Other 7.67 (7.24-8.13) 4.63 (4.29-4.98) 3.42 (3.113-3.74) 0.44 (0.34-0.57)
AAA, Abdominal aortic aneurysm; CAS, carotid artery stenosis; CI, conﬁdence interval; PAD, peripheral artery disease; PVD, peripheral vascular disease.
Fig 2. Prevalence of vascular disease according to the aggregate burden of modiﬁable risk factors in (A) men and (B)
women. Five modiﬁable risk factors (hypertension, hypercholesterolemia, smoking, diabetes, and sedentary lifestyle)
were considered. AAA, Abdominal aortic aneurysm; CAS, carotid artery stenosis; PAD, peripheral artery disease; PVD,
peripheral vascular disease.
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common in men than women, however, women were
more likely to have PAD and men were more likely to
have CAS and AAAs. The report of an increased prevalence
of PAD in women is not novel.10 Despite the difference in
prevalence of vascular disease between women and men,
the association between risk factors and prevalence of
PVD was remarkably consistent across sexes. Third, the
prevalence of any PVD was higher in blacks and Native
Americans. Finally, although the magnitude of each modi-
ﬁable risk factor and vascular disease varied according to
vascular disease phenotype, these data suggest that in this
population, the prevalence of PVD could potentially be
lower by improving modiﬁable risk factors with or without
pharmacologic therapy (assuming a causal relationship).
PVD represents a signiﬁcant cause of morbidity and
mortality. In its worst forms, it can be responsible for stroke,death from AAA rupture, and lower extremity amputation
secondary to gangrene. In subjects with less severe disease,
the risk of coronary disease, cerebrovascular disease, and
death are heightened, and quality of life is impaired. There
are data to suggest that subjects with asymptomatic vascular
disease have a poor prognosis.11-13 Therefore, knowledge
regarding the prevalence of PVD and the association
between each risk factor and vascular disease is of practical
importance.
Each modiﬁable risk factor has been found to be asso-
ciated with a higher risk of coronary heart disease and
mortality.14 It is estimated that optimal risk factor control
could prevent up to 100,000 deaths per year.15 Previous
reports by us and others have noted that smoking is
associated with an increased risk of cardiovascular death
and all-cause mortality.16,17 It is believed that nearly
two-thirds of deaths among active smokers could be
Table III. Modiﬁable risk factors andunadjusted andmultivariate-adjustedORof anyvascular disease, PAD,CAS, andAAAs
Risk factor
Any vascular disease PAD
Univariate OR (95% CI) Multivariatea OR (95% CI) Univariate OR (95% CI) Multivariatea OR (95% CI)
Smoking status
Never 1 [Ref] 1 [Ref] 1 [Ref] 1 [Ref]
Former 1.54 (1.53-1.55) 1.51 (1.49-1.53) 1.47 (1.46-1.50) 1.55 (1.53-1.57)
Active 1.87 (1.85-1.88) 2.06 (2.03-2.08) 1.95 (1.93-1.98) 2.26 (2.23-2.29)
Hypertension 2.18 (2.16-2.20) 1.59 (1.57-1.62) 2.26 (2.23-2.36) 1.60 (1.58-1.62)
Hyperlipidemia 1.57 (1.56-1.58) 1.28 (1.26-1.31) 1.35 (1.34-1.37) 1.05 (1.04-1.07)
Sedentary lifestyle 1.25 (1.24-1.26) 1.31 (1.29-1.33) 1.38 (1.37-1.39) 1.34 (1.32-1.36)
Diabetes 2.19 (2.17-2.22) 1.60 (1.58-1.62) 2.38 (2.34-2.41) 1.77 (1.74-1.79)
AAAs, Abdominal aortic aneurysms; CAS, carotid artery stenosis; CI, conﬁdence interval; PAD, peripheral artery disease; OR, odds ratio.
aAdjusted for age, sex, race/ethnicity, body mass index, family history of cardiovascular disease, and for all of the factors that appear in the table.
Table IV. Modiﬁable risk factors andunadjusted andmultivariate-adjustedPARof any vasculardisease,PAD,CAS, andAAAs
Risk factor
Any vascular disease PAD
Univariate PAR
(95% CI)
Multivariatea PAR
(95% CI)
Univariate PAR
(95% CI)
Multivariatea PAR
(95% CI)
Smoking status
Never 1 [Ref] 1 [Ref] 1 [Ref] 1 [Ref]
Former 14.25 (14.03-14.48) 13.57 (13.37-13.80) 12.64 (12.40-13.33) 14.48 (14.03-14.93)
Active 16.96 (16.64-17.12) 20.15 (19.63-20.23) 18.24 (17.92-18.71) 22.97 (22.69-23.52)
Hypertension 35.67 (35.28-36.06) 21.71 (21.42-22.00) 37.19 (36.63-38.99) 22.85 (22.28-23.40)
Hyperlipidemia 23.30 (22.99-23.61) 12.99 (12.58-13.39) 15.72 (15.34-16.47) 3.60 (3.10-4.10)
Sedentary lifestyle 12.44 (11.80-12.76) 11.47 (11.14-11.80) 20.32 (19.78-20.58) 17.29 (16.71-17.86)
Diabetes 11.39 (11.22-11.64) 6.09 (5.89-6.28) 12.97 (12.64-13.22) 7.77 (7.49-7.95)
AAAs, Abdominal aortic aneurysms; CAS, carotid artery stenosis; CI, conﬁdence interval; PAD, peripheral artery disease; PAR, population-attributable risk;
OR, odds ratio.
aAdjusted for age, sex, race/ethnicity, body mass index, family history of cardiovascular disease and for all of the factors that appear in the table.
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more than 70 million U.S. adults in 2009. Data suggest
that for every 10% increase in hypertension treatment,
14,000 additional deaths could be prevented.15 There is
a continuous, graded relationship of serum cholesterol
level and long-term risk of cardiovascular morbidity and
mortality.18 It is estimated that every 10% increase in treat-
ment of hyperlipidemia would prevent an additional 8,000
deaths per year.15 Many observational studies provide
evidence to link the presence of diabetes and physical
activity with cardiovascular morbidity and mortality.19,20
To control these risk factors, the National Diabetes
Prevention Program promotes weight loss, improved
nutrition, and increased physical activity among subjects
at increased risk.
Knowledge of the aggregate risk factor proﬁle on an
individual subject is clinically important. Our data indicate
that only 10% of the population has zero (of ﬁve) risk factors
present. These estimates are consistent with recent reports
demonstrating that large proportions of the U.S. adult
population have poor risk factor control.21,22 Improving
an individual’s risk factor proﬁle could theoretically havea signiﬁcant impact on PVD.23 For example, decreasing
an individual’s number of risk factors from three to zero
would theoretically result (assuming a causal relationship)
in a reduction of the overall prevalence of vascular disease
in an individual subject z fourfold (from 10.7% to 2.8%).
While this may appear to be a lofty goal, certainly cessation
of cigarette smoking and an increase in physical exercise are
clearly attainable objectives on an individual patient basis.
Certainly, we cannot prove based on the results of this
particular study that these types of risk factor modiﬁcation
would reduce the speciﬁc complications of carotid artery
disease, PAD, or aortic aneurysms. However, there is abun-
dant evidence that risk factor modiﬁcation in individuals
with generalized atherosclerosis will improve cardiovascular
morbidity and mortality overall. These individuals represent
a target population that requires improved lifestyle with or
without a polypharmacological approach. With this in
mind, initiatives have been set up to target cardiovascular
prevention strategies.24-26
While the data for our study emanate from a large
vascular screening project, in general, screening large pop-
ulations for the presence of PVD remains controversial.
CAS AAA
Univariate OR (95% CI) Multivariatea OR (95% CI) Univariate OR (95% CI) Multivariatea OR (95% CI)
1 [Ref] 1 [Ref] 1 [Ref] 1 [Ref]
1.49 (1.47-1.51) 1.42 (1.40-1.45) 2.57 (2.51-2.63) 1.98 (1.86-2.03)
1.69 (1.66-1.71) 1.77 (1.75-1.80) 3.14 (3.06-0.22) 2.75 (2.68-2.82)
2.26 (2.23-2.28) 1.62 (1.59-1.64) 1.76 (1.72-1.80) 1.24 (1.21-1.28)
1.80 (1.78-1.82) 1.45 (1.43-1.46) 1.66 (1.62-1.69) 1.45 (1.41-1.49)
1.16 (1.15-1.17) 1.17 (1.16-1.18) 1.16 (1.14-1.18) 1.00 (1.00-1.00)
2.18 (2.15-2.21) 1.60 (1.57-1.63) 1.32 (1.28-1.37) 1.00 (1.00-1.00)
Table III. Continued.
CAS AAA
Univariate PAR (95% CI) Multivariatea PAR (95% CI) Univariate PAR (95% CI) Multivariatea PAR (95% CI)
1 [Ref] 1 [Ref] 1 [Ref] 1 [Ref]
13.11 (12.64-13.57) 11.69 (11.21-12.17) 32.58 (31.73-33.41) 23.72 (22.81-24.60)
13.94 (13.42-14.29) 15.48 (15.14-15.81) 33.44 (32.60-34.26) 29.59 (28.41-30.17)
37.19 (36.63-37.56) 23.40 (23.12-23.95) 26.32 (25.28-27.33) 10.14 (8.98-11.26)
29.89 (29.37-30.41) 20.03 (19.35-20.37) 26.02 (24.84-26.89) 19.69 (18.65-20.71)
7.72 (7.00-8.07) 7.36 (6.99-7.72) 7.00 (5.90-8.07) 5.90 (4.78-6.63)
11.30 (11.05-11.56) 6.00 (5.80-6.18) 3.34 (2.94-3.84) 3.14 (2.83-3.44)
Table IV. Continued.
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screening been clearly demonstrated in randomized
controlled trials27; of note, such screening of men aged
64 to 73 was found to be cost-effective as well. For
PAD, screening and early identiﬁcation could potentially
avoid the progression of PAD itself and could improve
risk management of future cardiovascular disease, coronary
disease, and stroke.28 However, a recent systematic review
on this topic found that there was a considerable amount of
disagreement across screening guidelines because of the
lack of clear-cut evidence of the value of PAD screening
in the general population.28 Finally, screening asymptom-
atic individuals for carotid stenosis remains controversial
despite the recognition that carotid bifurcation disease is
a major cause of stroke.29 Prior screening studies have
identiﬁed carotid artery disease as the most commonly
diagnosed potential cause of ischemic stroke in asymptom-
atic populations, compared with hypertension or atrial
ﬁbrillation.29 The main obstacles to screening include difﬁ-
culty in identifying populations with a high prevalence of
disease to justify the cost and effort and concerns among
some regarding the beneﬁt of carotid endarterectomy andangioplasty and stenting in patients with asymptomatic
carotid artery disease.30
The present study has several strengths, including
a very large number of women and men and subject of
different race/ethnicities across the United States from
more than 20,000 centers, with a large number of subjects
with each type of PVD. This allows excellent power
yielding better precision of prevalence estimates and facili-
tates adjustment for multiple covariates. Importantly, all
subjects had vascular screening studies using simple nonin-
vasive validated procedures that have high sensitivity and
speciﬁcity. Finally, we provide 95% CIs surrounding the
prevalence of disease and percentage of PAR, which are
essential for describing estimation uncertainty.
Limitations. Several limitations should be considered.
First, the study population is a self-referred population
who paid out of pocket for their screening test, raising
the issue of selection bias, which may limit the generaliz-
ability of these ﬁndings. If this population represented
a wealthier or better-educated group, then perhaps this
segment of the population would have a lower prevalence
of disease than a less-educated or more socioeconomically
Table V. Prevalence and 95% CI of PVD by number of modiﬁable risk factors present
No. %
Prevalence of any
vascular disease (95% CI)
Prevalence of
PAD (95% CI)
Prevalence of
CAS (95% CI)
Prevalence of
AAA (95% CI)
Risk factors present
0 349,091 9.44 2.76 (2.71-2.82) 1.18 (1.14-1.22) 1.41 (1.37-1.45) 0.31 (0.29-0.33)
1 1,058,972 28.65 4.63 (4.59-4.67) 2.09 (2.06-2.12) 2.36 (2.33-2.39) 0.54 (0.53-0.55)
2 1,213,440 32.82 7.12 (7.07-7.17) 3.28 (3.25-3.31) 3.72 (3.69-3.75) 0.85 (0.83-0.87)
3 790,083 21.37 10.73 (10.66-10.80) 5.14 (5.09-5.19) 5.73 (5.68-5.78) 1.28 (1.26-1.31)
4 254,254 6.88 16.00 (15.86-16.14) 8.32 (8.21-8.43) 8.48 (8.37-11.94) 1.82 (1.77-1.87)
5 30,938 0.84 22.08 (21.62-22.55) 12.43 (12.07-12.80) 11.58 (11.23-11.94) 2.39 (2.22-2.57)
AAA, Abdominal aortic aneurysm; CAS, carotid artery stenosis; CI, conﬁdence interval; PAD, peripheral artery disease; PVD, peripheral vascular disease.
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these subjects were motivated to undergo vascular
screening examinations because they already harbored
some known risk factors for vascular disease. The exact
effect of these biases, of course, cannot be completely eluci-
dated. Of note, the prevalence of risk factors measured in
the current study mirror those of the population of the
United States. Compared with the National Health and
Nutrition Examination Survey (a survey of the civilian,
noninstitutionalized population of the United States), the
Lifeline database had a similar prevalence of cardiovascular
risk factors, including hypertension (45% and 45%), hyper-
lipidemia (45% and 51%), diabetes mellitus (10% and 11%),
and current smoking (20% and 22%).2
Second, each risk factor was weighted the same, which
implies that each of them are of equal importance. This
may lead to heterogeneity among people being classiﬁed
in the same category. Third, PAR assumes a causal relation-
ship between the modiﬁable risk factors and prevalence of
PVD. Although this is a large assumption, this was a care-
fully performed observational study, which may provide
a reasonable approach for evaluating the association of
modiﬁable risk factors on the prevalence of vascular
diseases. Finally, residual confounding from unmeasured
variables may modify the association of risk factors and
vascular diseases. Nonetheless, other validated and tested
risk scores for incident cardiovascular diseases contain
many of the same variables measured in the current study.3CONCLUSIONS
The prevalence of PVD in the United States pop-
ulation is signiﬁcant. Certain demographic groups are
particularly affected; however, differences exist across the
spectrum of vascular disease. As noted, modiﬁable risk
factors are present in the population and an important
public health problem in the United States. The association
of modiﬁable risk factors and increasing prevalence of PVD
suggest a potential therapeutic target for the prevention of
disease in different peripheral circulations. Our data suggest
that consequences of current smoking and hypertension are
most attributable to the increased prevalence of PVDs. It is
plausible that an education campaign about the health
beneﬁts of cardiovascular risk factor control may havesome beneﬁts in decreasing the prevalence of PVDs in
the population.
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characteristics of study participants included in the
analysis
Characteristic
Study
participants
(n ¼ 3,696,778)
Excluded
participants
(n ¼ 374,785)
Age, years 64.1 6 10.2 63.84 6 14.6
Female sex, % 62.5 64.1
Race or ethnic group, %
White 85.8 85.8
Black 3.0 1.9
Hispanic 2.4 2.7
Asian 1.9 1.6
Native American 2.8 2.9
Other 0.6 0.6
Body mass index, kg/m2 27.4 6 6.07 26 6 6.21
Obesity,a % 27.6 23.6
Cigarette smoking status, %
Never smoked 59.7 63.0
Former smoker 30.8 28.4
Current smoker 23.5 20.9
Hypertension, % 47.0 45.2
Hyperlipidemia, % 53.3 48.4
Diabetes mellitus, % 10.8 10.8
Sedentary, % 58.2 59.4
Family history of
cardiovascular disease, %
23.0 23.5
aObesity is deﬁned by a body mass index >30 kg/m2.
